A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight
Eli Lilly and Company
View at source ↗Clinical trial
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Brief summary
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks. Participants with prediabetes will continue in the extension for another 2 years.
Source: ClinicalTrials.gov (U.S. National Library of Medicine), data processed 2026-10-29T09:00:05; modifications: selected fields only; whitespace normalized; brief summary truncated to 2,000 characters. Not a U.S. Government endorsement.
Trial details
- acronym
- SURMOUNT-1
- status
- COMPLETED
- phase
- PHASE3
- study type
- INTERVENTIONAL
- enrollment
- 2539
- sponsor
- Eli Lilly and Company
- conditions
- Overweight; Obesity
- interventions
- DRUG: Tirzepatide; DRUG: Placebo
- start date
- 2019-12-04
- start date type
- ACTUAL
- primary completion date
- 2022-04-01
- has results
- true
- data source
- ClinicalTrials.gov
- data processed
- 2026-10-29T09:00:05
- modifications
- selected fields only; whitespace normalized; brief summary truncated to 2,000 characters
Record
- Archive ID
- nct:NCT04184622
- Published
- Dec 3, 2019
- Updated
- Jul 24, 2025
- Venue
- ClinicalTrials.gov
- ClinicalTrials.gov
- NCT04184622
- Categories
- Overweight, Obesity
- License
- ClinicalTrials.gov terms (attribution, processing date, modifications noted)
- Provenance
- clinicaltrials